Closed Loop Artificial Pancreas Systems for Glycemic Optimization in Pediatric Type 1 Diabetes
Type 1 diabetes in children is characterized by autoimmune destruction of pancreatic beta cells, resulting in absolute insulin deficiency and lifelong dependence on exogenous insulin therapy. Despite substantial progress in insulin analogues and continuous glucose monitoring technologies, achieving stable glycemic control in pediatric populations remained challenging due to physiological variability, growth-related hormonal fluctuations, and behavioral factors that predispose to both hypoglycemia and hyperglycemia. Closed-loop artificial pancreas systems, which integrated continuous glucose sensing with algorithm-driven insulin delivery, represented a transformative approach to glycemic optimization. The purpose of this review was to critically examine the biochemical rationale, technological architecture, clinical performance, safety considerations, and future translational directions of closedloop systems in pediatric Type 1 diabetes. This article was developed through structured critical analysis of peerreviewed clinical trials, engineering studies, and metabolic research literature. Accumulating evidence demonstrated that closed-loop systems significantly increased time in target glycemic range, reduced nocturnal hypoglycemia, and improved overall metabolic stability compared with conventional insulin pump therapy. However, challenges related to sensor lag, insulin pharmacokinetics, device adherence, and equitable access remained. Closed-loop artificial pancreas systems offer substantial potential to transform pediatric diabetes management, and continued technological refinement alongside broad clinical implementation is warranted.